Communiqués de presse d'Aji Bio-Pharma Communiqués de presse February 22, 2023 Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase En savoir plus January 10, 2023 Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer En savoir plus March 3, 2022 Ajinomoto Bio-Pharma Services Awarded Two ‘CMO Leadership Awards’ En savoir plus January 25, 2022 Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance En savoir plus 25 mai 2021 Ajinomoto Bio-Pharma Services renforce ses capacités de remplissage et de conditionnement grâce à une nouvelle unité de remplissage polyvalente En savoir plus March 30, 2021 Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing En savoir plus March 29, 2021 Ajinomoto Co., Inc. and Bright Peak Therapeutics Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines En savoir plus 27 janvier 2021 Ajinomoto Bio-Pharma Services et Humanigen étendent leur accord de fabrication afin de prendre en charge le conditionnement d’un traitement expérimental contre la COVID-19, le lenzilumab, dont l’étude de phase III touche à sa fin En savoir plus December 22, 2020 Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection En savoir plus October 6, 2020 First Commercial Drug Manufactured via Ajinomoto Bio-Pharma Services’ AJIPHASE Technology Receives FDA Approval En savoir plus September 29, 2020 Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic En savoir plus August 13, 2020 Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility En savoir plus Chargement…Afficher plus
